Form 4: Acrivon Therapeutics Director Acquires RSUs

Charles M. Baum, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.

Summary

• Charles M. Baum, a Director at Acrivon Therapeutics, Inc. (ACRV), acquired 9,366 restricted stock units (RSUs) on May 18, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The RSUs are scheduled to vest in full on May 18, 2027, provided Mr. Baum remains in continuous service with the company through that date.
• Following this transaction, Mr. Baum beneficially owns 9,366 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard equity grant to a director, indicating alignment of interests, but does not reflect new financial performance or strategic shifts.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The acquisition of RSUs represents a long-term incentive for the director, aligning their interests with shareholders.

Risks

• The RSUs are subject to vesting conditions, meaning the director may not ultimately receive the shares if their service is not continuous.
• The value of the RSUs is tied to the future performance and stock price of Acrivon Therapeutics.

Future Outlook

The RSUs will vest on May 18, 2027, subject to the reporting person's continuous service.

Industry Context

StockSavvy.ai notes that insider acquisitions of equity, particularly in the biotechnology sector, can be interpreted as a positive signal of management's belief in the company's pipeline and future growth potential.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, suggesting confidence in the company's long-term value. However, it does not immediately impact share price or dividends.
• Employees: The vesting condition reinforces the importance of continued service for key personnel.
• Management: The grant aligns the director's incentives with the company's performance.

Next Steps

• The RSUs will vest on May 18, 2027, contingent upon continued service.
• The acquired shares will be beneficially owned by Charles M. Baum following the vesting period.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, SEC Filing, Insider Trading, Restricted Stock Units, RSUs, Director, Equity Award, Vesting